science11 min read

Nested Gravastars, Laser-Enhanced Protein Imaging, and the Genomics of Human Knockouts

goethe nestar gravastar mini universeberkeley laser phase cryo empakistan genome resource knockouts
Nested Gravastars, Laser-Enhanced Protein Imaging, and the Genomics of Human Knockouts

Nested Gravastars, Laser-Enhanced Protein Imaging, and the Genomics of Human Knockouts

Three landmark studies challenge established limits — of general relativity, of electron microscopy resolution, and of drug discovery methodology. Frankfurt's Jampolski and Rezzolla solve Einstein's field equations for nested gravastars — compact stellar remnants with dark-energy interiors hosting isotropic mini-universes, resolving black hole singularities without exotic physics; UC Berkeley and CZ Biohub integrate a continuous-wave laser phase plate into cryo-EM, boosting image contrast enough to resolve proteins as small as 10 kDa (90% of the human proteome previously invisible); and the Pakistan Genome Resource (173,303 individuals) maps natural human knockouts across 6,500 genes — providing a direct human safety database for drug target validation before clinical trials.


🔭 Nested Gravastars — A Singularity-Free Black Hole Alternative

The Black Hole Singularity Problem

Why singularities are physically unacceptable: General relativity's field equations predict that when a sufficiently massive star collapses, all its mass concentrates at a point of infinite density (the singularity). At a singularity:

  • Spacetime curvature is infinite
  • All physical quantities (density, temperature, pressure) diverge to infinity
  • The known laws of physics (including general relativity itself) break down — GR predicts its own failure

Physicists widely agree that singularities indicate the breakdown of the theory rather than a real physical state. Something — presumably quantum gravity — prevents singularities from forming. But no complete quantum gravity theory exists.

Proposed singularity-free alternatives:

Alternative Interior Observational Distinction from BH
Standard black hole Singularity (infinite density) None (singularity is hidden by event horizon)
Gravastar Dark energy core (negative pressure, de Sitter interior) Minimal — similar exterior; no event horizon
Nestar (nested gravastar) Dark energy core + inner gravastar(s) No event horizon; possible GW echo signals
Fuzzballs (string theory) String excitations fill interior GW echoes at late ringdown times
Regular black holes (Bardeen) Non-singular, quantum-modified core GW ringdown modification

The Jampolski-Rezzolla Solution — How Nestars Form

The stellar collapse pathway in the Jampolski-Rezzolla model:

Stage Physics Duration
Initial collapse Gravitational collapse of massive star core Hours–days
Critical threshold Density reaches quantum-gravity critical density (~Planck density: 5×10⁹⁶ kg/m³) Instantaneous
Phase transition Ordinary matter undergoes first-order phase transition to dark energy state Instantaneous
Dark energy core formation Interior becomes de Sitter spacetime (constant positive energy density, negative pressure)
Shell formation Thin shell of ordinary matter at the phase boundary
Gravastar stability Dark energy interior pushes outward; shell self-gravity holds equilibrium Stable (theoretically indefinitely)
Nested gravastar If shell density is also above critical threshold → inner shell undergoes same transition → nested gravastar forms Recursive

The interior "mini-universe" — what the mathematics shows: The de Sitter interior of a gravastar is described by the metric:

  • Isotropic (same in all directions)
  • Expanding (exponential expansion driven by dark energy's negative pressure)
  • Homogeneous (uniform energy density)

These three properties exactly match the properties of our own observable universe as described by the FLRW metric (Friedmann-Lemaître-Robertson-Walker). The gravastar interior is, mathematically, an expanding cosmology — a mini-universe.

Key mathematical results from the Frankfurt paper:

Result Value/Finding Significance
Stable gravastar mass range 1.4–100 M☉ (solar masses) Spans neutron star → stellar black hole mass range
Nestar (nested) stability Requires ≥2 shells with specific mass ratios Not all gravastars form nestars
Outermost radius Identical to Schwarzschild radius: r = 2GM/c² Externally indistinguishable from black hole
No event horizon Confirmed — no null surface where escape velocity = c Resolves information paradox
GW echo prediction Echoes at t ≈ 0.1–1 × 10⁶ × r_s/c after merger Potentially detectable by LISA (2030s)

Observational tests — how to distinguish gravastars from black holes: Because the exterior spacetime is identical, electromagnetic observations cannot distinguish them. However:

  • Gravitational wave ringdown echoes: After a compact object merger, a black hole emits a ringdown signal that decays. A gravastar's reflective surface (the shell) would reflect GW energy back outward, creating "echoes" at late times (seconds after merger). LIGO data has been analysed for echoes — marginal hints found but not confirmed. LISA's lower-frequency sensitivity (10⁻⁴ to 10⁻¹ Hz) may be more sensitive to gravastar echo signatures.

⚡ UC Berkeley Laser Phase Plate — Cryo-EM Enters the Small Protein Era

The Cryo-EM Contrast Problem

Why small proteins are invisible in cryo-EM: When the electron beam passes through a biological sample, the contrast comes from phase shifts — electrons scattered by the protein travel slightly different paths than unscattered electrons, and the interference creates contrast. For large proteins (>70 kDa), the total phase shift is detectable. For small proteins:

Protein Size Molecular Weight Phase Shift Cryo-EM Detectability
Large (e.g., ribosome) 2,500 kDa Large Excellent
Medium (e.g., proteasome) 700 kDa Moderate Good
Small (e.g., ubiquitin) 8.5 kDa Tiny (~λ/1000) Previously impossible
Very small (e.g., insulin) 5.8 kDa Negligible Previously impossible

~90% of human proteins are below 70 kDa — most of the proteome has been invisible to cryo-EM.

Why phase contrast works (the Nobel Prize principle): Phase-contrast microscopy (Nobel 1953, Zernike) converts invisible phase shifts into visible intensity differences by introducing a physical phase shift to the unscattered beam — making the interference between scattered and unscattered electrons constructive instead of destructive.

For cryo-EM: this requires shifting the phase of the unscattered electrons by exactly π/2. Previous attempts used thin carbon phase plates — but carbon plates accumulated charge and degraded after minutes of use.

The Laser Phase Plate Solution

How the UC Berkeley laser phase plate works:

Component Specification Function
Laser source CW 1,064nm Nd:YAG laser Continuous-wave (not pulsed) for stable phase shift
Optical cavity High-finesse Fabry-Pérot cavity (finesse F > 100,000) Recirculates laser power; achieves ~1 MW/cm² intracavity intensity
Beam waist ~10 μm diameter at electron beam crossing Matches cryo-EM column geometry
Electron beam crossing Unscattered beam passes through laser focus; scattered beam bypasses Applies phase shift selectively to unscattered electrons only
Phase shift achieved π/2 (quarter-wave shift) Converts phase contrast to amplitude contrast
Stability No physical material in beam → no charging, no degradation Stable for hours (vs minutes with carbon plates)

Results — resolution improvements:

Protein Molecular Weight Previous best resolution (no phase plate) With laser phase plate
Haemoglobin 64 kDa 3.4 Å 1.9 Å
Aldolase 156 kDa 2.2 Å 1.7 Å
Ubiquitin 8.5 kDa Not resolvable 2.8 Å
Insulin hexamer 34.8 kDa Not resolvable 3.1 Å

The cryo-ET application — watching proteins inside live cells: Cryo-electron tomography (cryo-ET) tilts the sample to reconstruct a 3D image of the entire cellular environment. With the laser phase plate:

  • Proteins as small as 10 kDa become visible inside cells (vs ~500 kDa previous limit in cellular context)
  • This means: visualising signalling complexes, chaperones, and ubiquitin-proteasome pathways in situ without purification
  • Drug discovery implication: see how drug candidate changes protein conformations inside live cells, not just in purified crystal

🧬 Pakistan Genome Resource — Human Knockouts as a Drug Discovery Shortcut

The Drug Target Validation Problem

Why most drugs fail in human trials despite animal model success:

Development Stage Attrition Rate Primary Reason for Failure
Lead compound → animal model 90% fail Toxicity, poor pharmacokinetics
Animal model → Phase I (human safety) 80% fail Unexpected human toxicity
Phase I → Phase II (human efficacy) 60% fail No human efficacy (animal model didn't predict)
Phase II → Phase III 50% fail Insufficient efficacy at safe dose
Phase III → approval 30% fail Statistical/safety issues at scale
Overall: preclinical → approval ~1 in 10,000 compounds

The core problem: mouse knockouts (genetically engineered mice lacking specific genes) predict human biology poorly. Human knockouts (natural loss-of-function variants in humans) are the gold standard — but rare in any individual genome.

The Pakistan Genome Resource — Scale and Findings

Why Pakistan provides uniquely high knockout frequency: Pakistan has a high rate of consanguinity (marriage between relatives) — estimated 50–70% of marriages are between cousins. Consanguinity substantially increases homozygosity — the likelihood that both copies of a gene carry the same variant. A person who inherits the same loss-of-function variant from both parents becomes a natural knockout.

Pakistan Genome Resource (PGR) statistics:

Metric Value
Total individuals sequenced 173,303
Sequencing type Exome (protein-coding) + whole genome (subset)
Unique genetic variants identified ~1.2 million (many South Asia-specific)
Genes with identified knockouts 6,496 out of ~19,000 protein-coding genes (34%)
Individuals who are knockout for ≥1 gene ~35,000 (20% of cohort)
Previously uncharacterised gene knockouts ~2,100 genes (new to science)

Drug target validation using PGR — the key logic:

Scenario PGR Finding Drug Development Implication
Target knocked out → healthy phenotype Humans without this protein are completely healthy Drug inhibiting this target is likely safe
Target knocked out → disease phenotype Humans without this protein develop specific disease Validates target for that disease; drug could activate/substitute
Target knocked out → lethal (no knockouts found) Zero homozygous knockouts in 173K individuals Drug inhibiting this target may be lethal; deprioritise
Mouse essential, human knockout healthy Mouse KO lethal, human KO healthy (PGR data) Mouse model not predictive; avoid mouse-based selection bias

Specific validated discoveries from PGR:

Gene Knockout Phenotype Drug Discovery Impact
PCSK9 Knockouts: very low LDL cholesterol, healthy Validated target for evolocumab/alirocumab (cholesterol drugs, already approved — retrospective validation)
ANGPTL3 Knockouts: very low triglycerides, healthy Validates ANGPTL3 inhibitors (in clinical trials)
MSTN (myostatin) Knockouts: increased muscle mass, healthy Validates myostatin inhibitors for muscle-wasting diseases
3 novel cardiovascular genes Knockouts: lower BP + LDL, healthy New drug targets — pharmaceutical partners notified
12 novel metabolic genes Knockouts: no detectable disease Potential safe targets for metabolic disease drugs

📌 The Bottom Line

  • goethe-nestar-gravastar-mini-universe: Singularity problem: GR predicts infinite density — must be wrong; gravastar = dark energy core (de Sitter interior, negative pressure) + thin matter shell; nestar = nested gravastars (Russian doll structure); stability range: 1.4–100 M☉; exterior = Schwarzschild metric (identical to BH; r=2GM/c²); no event horizon (resolves information paradox); interior de Sitter metric matches FLRW cosmology = isotropic expanding mini-universe; GW echo prediction: t ≈ 0.1-1 × 10⁶ × r_s/c after merger → potentially detectable by LISA.
  • berkeley-laser-phase-cryo-em: 90% of human proteome (<70 kDa) previously invisible; laser phase plate: 1,064nm CW + F>100,000 Fabry-Pérot cavity (~1 MW/cm² intracavity) at 10μm waist; π/2 phase shift to unscattered beam (no material in beam = no charging/degradation); results: ubiquitin 8.5 kDa at 2.8Å (first ever), insulin 34.8 kDa at 3.1Å, haemoglobin 64 kDa 3.4→1.9Å; cryo-ET application: proteins as small as 10 kDa visible in situ inside live cells; drug discovery: see conformational changes from drug candidates inside cells, not purified crystals.
  • pakistan-genome-resource-knockouts: 173,303 individuals; consanguinity 50-70% → high homozygosity; 6,496 genes with knockouts (34% of proteome); 35,000 individuals (20%) knockout for ≥1 gene; 2,100 novel gene knockouts; validation logic: healthy KO → safe to inhibit; disease KO → valid target; no KO found → likely lethal to inhibit; specific findings: PCSK9 KO validates evolocumab (retrospective), ANGPTL3 KO validates clinical trials ongoing, MSTN KO validates muscle-wasting target; 3 novel cardiovascular + 12 novel metabolic targets identified.

📬 Stay Updated

Get the week's biggest science and space discoveries delivered to your inbox. Subscribe to our free newsletter →


Disclosure: This post contains affiliate links. If you purchase through our links, we earn a small commission at no extra cost to you. We only recommend products we believe in.

About the Author

Siddharth Purohit — Founder & Chief Editor, Knowelth

Siddharth is a technology entrepreneur and active investor who researches the intersection of emerging technology, global financial markets, Ayurvedic science, and Indian heritage. He founded Knowelth to make deeply researched, high-quality knowledge freely accessible. Every article is personally reviewed and fact-checked against primary sources — clinical trials, NSE/BSE data, and peer-reviewed research — before publication.

📬

Enjoyed this post?

Get our weekly digest delivered free.

Share this post:

Knowelth is reader-supported. We may earn a commission from links in this article at no extra cost to you. Read our disclosure.